AXITINIB (AG-013736) AS SECOND LINE THERAPY FOR METASTATIC RENAL CELL CANCER: AXIS TRIAL
AXITINIB (AG-013736) AS SECOND LINE THERAPY FOR METASTATIC RENAL CELL CANCER: AXIS TRIAL
The study is designed to demonstrate that axitinib (AG-013736) is superior to sorafenib in delaying tumor progression in patients with metastatic renal cell cancer after failure of one first line regimen.
Inclusion Criteria:
Exclusion Criteria:
Washington D.C., District of Columbia 20007, United States
Hackensack, New Jersey 07601, United States
Hackensack, New Jersey 07601, United States
New York, New York 10065, United States
Columbus, Ohio 43210, United States
Greenville, South Carolina 29615, United States
Seattle, Washington 98101, United States
Vienna, 1020, Austria
Porto Alegre, Rio Grande do Sul 90050-170, Brazil
Kelowna, British Columbia V1Y 5L3, Canada
Beijing, Chaoyang District 100021, China
Nanjing, Jiangsu 210002, China
Shanghai, 200127, China
Mainz, 55131, Germany
München, 81377, Germany
Oldenburg, 26133, Germany
Brescia, 25123, Italy
Roma, 00152, Italy
Tsukuba, Ibaraki 305-8577, Japan
Sunto-gun, Shizuoka 411-8777, Japan
Arakawa-ku, Tokyo 116-8567, Japan
Chuo-Ku, Tokyo 104-0045, Japan
Itabashi-ku, Tokyo 173-8610, Japan
Shinjuku-ku, Tokyo 160-8582, Japan
Shinjuku-ku, Tokyo 162-8666, Japan
Ube-shi, Yamaguchi 755-8505, Japan
Poznan, 60 569, Poland
Obninsk, Kaluga Oblast 249036, Russia
Moscow, 123060, Russia
Goyang-si, Gyeonggi-do 410-769, South Korea
Busan, 602-715, South Korea
Seoul, 137-701, South Korea
Kaohsiung Hsien, 833, Taiwan
Bebington, Wirral, CH63 4JY, United Kingdom
Surrey, SM2 5PT, United Kingdom